Online inquiry

IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12482MR)

This product GTTS-WQ12482MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL20 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001385165.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50604
UniProt ID Q9NYY1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12482MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11074MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ3034MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ13115MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ1027MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ15919MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ11600MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW